Phenotypic features of BHK-21 cells used for production of foot-and-mouth disease vaccine

Biologicals

Volumn 25, Issue 1, 1997, Pages 65-73

  Amadori, M ^a   Volpe, G ^b   Defilippi, P ^b   Berneri, C ^a  

^a ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLA LOMBARDIA E DELL EMILIA ROMAGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; AZIRIDINE; FOOT AND MOUTH DISEASE VACCINE; INTEGRIN; VIRUS RECEPTOR; VIRUS RNA;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL STRAIN BHK; CELL SURFACE; CELL SUSPENSION; CELL VIABILITY; CONTROLLED STUDY; DISEASE PREDISPOSITION; MONOLAYER CULTURE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINE PRODUCTION; VIRUS CAPSID; VIRUS INACTIVATION; VIRUS PARTICLE;

ANIMALIA; FOOT-AND-MOUTH DISEASE VIRUS; MIRIDAE;

EID: 17544394497     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1996.0061     Document Type: Article

References (38)

1. 1. Capstick PB, Telling RC, Chapman WG et al. Growth of a cloned strain of hamster kidney cells in suspended cultures and their susceptibility to the virus of foot-and-mouth disease. Nature (Lond) 1962; 195: 1163-1164.
2. 2. Cowan KM, Erol N, Whiteland AP. Heterogenity of type Asia-1 foot-and-mouth disease virus and BHK-21 cells and the relationship to vaccine preparation. Bull Off Int Epiz 1974; 81: 1271-1298.
3. 3. Meloen RH. Localisation on foot-and-mouth disease virus (FMDV) of an antigenic deficiency induced by passage in BHK cells. Arch Virol 1976; 51: 299-306.
4. 4. Amadori M, Berneri C, Archetti IL. Immunogenicity of foot-and-mouth disease virus grown in BHK-21 suspension cells. Correlation with cell ploidy alterations and abnormal expression of the α5β1 integrin. Vaccine 1994; 12: 159-166.
5. 5. Nardelli L, Panina GF. The use of suspension cultures for FMD vaccine production. Criteria for the evaluation of cells, virus and vaccine. Dev Biol Standard 1977; 35: 9-25.
6. 6. Bahnemann HG. Binary ethyleneimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Arch Virol 1975; 47: 47-56.
7. 7. Barteling SJ. The use of frozen cells in the agar-cell suspension titration technique. Arch ges Virusf 1972; 38: 271-273.
8. 8. Amadori M, Barei S, Melegari M et al. Safety and efficacy of foot-and-mouth disease vaccines containing endonuclease-inactivated virions. Vaccine 1987; 5: 219-222.
9. 9. Capucci L, Brocchi E, De Simone F et al. Characterization of monoclonal antibodies produced against foot-and-mouth disease virus. Session of the Research Group of the European Commission for the Control of Foot-and-Mouth Disease, Brescia, Italy, June 26-28 1984; pp. 32-39.
10. 10. Xie Q-C, McCahon D, Crowther JR, Belsham GJ, McCullough KC. Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. J Gen Virol 1987; 68: 1637-1647.
11. 11. Crowther JR. Specific quantification of whole particles of foot-and-mouth disease virus in a sandwich ELISA using a monoclonal antibody. Session of the Research Group of the European Commission for the Control of Foot-and-Mouth Disease, Lindholm, Denmark, 25-29 June 1990, pp 67-72.
12. 12. Tarone G, Russo MA, Hirsch E, Odorisio T, Altruda F, Silengo L, Siracusa G. Expression of β1 integrin complexes on the surface of unfertilized mouse oocyte. Development 1993; 117: 1369-1375.
13. 13. Te Velde A, Klomp JPG, Yard BA et al. Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. J Immunol 1988; 140: 1548-1554.
14. 14. Sonnenberg A, Modderman PW, Hogervorst F. Laminin receptor on platelets is the integrin VLA-6. Nature (Lond) 1988; 336: 487-489.
15. 15. Defilippi P, Silengo L, Tarone G. α6β1 integrin (laminin receptor) is down-regulated by tumor necrosis factor α and interleukin-1 β in human endothelial cells. J Biol Chem 1992; 267: 18303-18307.
16. 16. Arunachalam B, Talwar GP, Raghupathy R. A simplified ELISA (CELISA) for the detection of antibodies reacting with cell-surface antigens. J Immunol Methods 1990; 135: 181-189.
17. 17. Meier T, Arni S, Malarkannan S et al. Immunodetection of biotinylated lymphocyte-surface proteins by enhanced chemiluminescence: a nonradioactive method for cell-surface protein analysis. Anal Biochem 1992; 204: 220-226.
18. 18. Fischer J, Maddox C, Moxley R, Kinden D, Miller M. Pathogenicity of a bovine attaching effacing Escherichia coli isolate lacking Shiga-like toxins. Am J Vet Res 1994; 55: 991-999.
19. 19. Brown F, Cartwright B. Purification of radioactive foot-and-mouth disease virus. Nature (Lond) 1963; 199: 1168-1170.
20. 20. Bolwell C, Brown AL, Barnett PV et al. Host cell selection of antigenic variants of foot-and-mouth disease virus. J Gen Virol 1989; 70: 45-57.
21. 21. White JM. Integrins as virus receptors. Curr Biol 1993; 3: 596-599.
22. 22. Hiller G, Weber K, Schneider L et al. Interaction of assembled progeny pox viruses with the cellular cytoskeleton. Virology 1979; 98: 142-153.
23. 23. Stallcup KC, Raine CS, Fields BN. Cytochalasin B inhibits the maturation of measles virus. Virology 1983; 124: 59-74.
24. 24. Superti F, Seganti L, Orsi N. Effect of cellular inhibitors on the infection of various susceptible cells with vesicular stomatis virus. Acta Virol 1988; 32: 487-493.
25. 25. Conti C, Superti F, Divizia M et al. Effect of inhibitors of cytoplasmic structures and functions on rabies virus infection in vitro. Comp Immun Microbiol Infect Dis 1990; 13: 137-146.
26. 26. De BP, Burdsall AL, Banerjee AK. Role of cellular actin in human parainfluenza virus type 3 genome transcription. J Biol Chem 1993; 268: 5703-5710.
27. 27. Grigera PR, Sagedahl A. Cytoskeletal association of an aphthovirus-induced polypeptide derived from the P3ABC region of the viral polyprotein. Virology 1986; 154: 369-380.
28. 28. Grigera PR, Tisminetzky SG, Lebendiker MB et al. Presence of a 43-kDa host-cell polypeptide in purified aphthovirions. Virology 1988; 165: 584-588.
29. 29. Gomez Yafal A, Palma EL. Host cell modulation of foot-and-mouth disease virus procapsid synthesis. Vet Microbiol 1986; 12: 329-335.
30. 30. Fox G, Parry NR, Barnett PV et al. The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (Arginine-Glycine-Aspartic Acid). J Gen Virol 1989; 70: 625-637.
31. 31. Liebermann HT, Dölling R, Schmidt D et al. RGD-containing peptides of VP1 of foot-and-mouth disease virus (FMDV) prevent virus infection in vitro. Acta Virol 1991; 35: 90-93.
32. 32. Baxt B, Becker Y. The effect of peptides containing the arginine-glycine-aspartic acid sequence on the adsorption of foot-and-mouth disease virus to tissue culture cells. Virus Genes 1990; 4: 73-83.
33. 33. Berinstein A, Roivainen M, Hovi T et al. Antibodies to the vitronectin receptor (integrin αVβ3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J Virol 1995; 69: 2664-2666.
34. 34. Diamond MS, Springer TA. The dynamic regulation of integrin adhesiveness. Curr Biol 1994; 4: 506-517.
35. 35. D'Souza SE, Haas TA, Piotrowicz RS, Byers-Ward V, McGrath DE, Soule HR, Cierniewski C, Plow EF, Smith JW. Ligand and cation binding are dual functions of a discrete segment of the integrin β3 subunit: cation displacement is involved in ligand binding. Cell 1994; 79: 659-667.
36. 36. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. The FASEB J 1990; 4: 2868-2880.
37. 37. Chambers M et al. Chimeric hepatitis B vines core particles as probes for studying peptide-integrin interactions. J Virol 1996; 70: 4045-4052.
38. 38. Jackson et al. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J Virol 1996; 70: 5282-5287.